B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CNR1

MOLECULAR TARGET

cannabinoid receptor 1

UniProt: P21554NCBI Gene: 126812 compounds

CNR1 (cannabinoid receptor 1) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CNR1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Rimonabant5.39218
2cbd2.208
3cannabidiol2.208
4Meclizine1.102
5Caffeine0.691
6Fluoxetine0.691
7Losartan0.691
8Mianserin0.691
9Venlafaxine Hydrochloride0.691
10candesartan cilexetil [Supplementary Concept]0.691
11Chlorhexidine0.691
12Fenofibrate0.691

About CNR1 as a Drug Target

CNR1 (cannabinoid receptor 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented CNR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CNR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.